- Threading through the mizmaze of Bartter syndrome. Proesmans, Willem // Pediatric Nephrology;Jul2006, Vol. 21 Issue 7, p896
The story, described here in detail, started in 1962 with the publication of a seminal paper by Frederic Bartter et al. in the December issue of the American Journal of Medicine. The authors reported two pediatric patients with hitherto undescribed features, namely growth and developmental delay...
- Strengthening Brittle Bones. // Time;8/17/1970, Vol. 96 Issue 7, p49
The article discusses the causes of osteoporosis and its remedies. According to researcher Frederic C. Bartter, parathyroid hormone directs the removal of calcium from bone and its release into the blood and thyrocalcitonin controls the transfer of calcium from blood to bone. The research found...
- Inspra. // Formulary;Nov2002, Vol. 37 Issue 11, p553
Focuses on Pharmacia & Upjohn Inc.'s aldosterone blocker Inspra, generic name eplerenone. Use of Inspra for treating hypertension; Effectiveness and safety of the drug; Recommended dosage.
- Erratum. // Surgical Endoscopy;Dec2004, Vol. 18 Issue 12, p1828
Presents a correction on an article focusing on the effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure in pigs, published in a previous issue of the journal "Surgical Endoscopy."
- Fresh from the pipeline: Eplerenone. Brown, Ruth; Quirk, Jeremy; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Mar2003, Vol. 2 Issue 3, p177
In September 2002, eplerenone (Inspra; Pharmacia), the first selective aldosterone receptor antagonist, was approved by the FDA for the treatment of hypertension. Will it become as successful as established blockbuster drugs that also target the rennin-angiotensin-aldosterone system?
- Efficacy of spironolactone therapy in patients with heart failure with normal ejection fraction: The Authors' reply. Yip, Gabriel W. K.; Sanderson, John E. // Heart;May2010, Vol. 96 Issue 10, p791
A response to a letter to the editor about an article on the efficacy of aldosterone antagonists for the treatment of heart failure with normal ejection fraction is presented.
- Aldosterone blocker reduces mortality in post-MI heart failure patients. // Geriatrics;May2003, Vol. 58 Issue 5, p16
Reports that aldosterone blocker reduces mortality in the post-myocardial infarction failure patients. Benefits from eplerenone; Reduction in sudden cardiac death.
- Aldosterone Receptor Antagonists for Hypertension: What Do They Offer? Liew, Danny; Krum, Henry // Drugs;2003, Vol. 63 Issue 19, p1963
Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases. Its actions, once thought to be limited to the distal convoluted tubule of the kidney, are now recognised to be wide-ranging, including interactions with...
- Benefits and Consequences of Aldosterone Antagonists for HF. Kuritzky, Louis // OB/GYN Clinical Alert;Feb2013 Clinical Briefs in Primary Care, p3
The article focuses on the results of clinical trials regarding the benefits and consequences of aldosterone antagonist therapy in chronic heart failure (CHF) patients.